In a landmark achievement for the future of drug discovery, InSphero, the groundbreaking 3D in vitro model company, has successfully raised $12 million in funding. This investment reaffirms the confidence in InSphero's mission to modernize drug safety and efficacy testing, utilizing innovative spheroid-based models that empower researchers to unlock their full potential. With this latest round of funding, InSphero aims to further enhance its capabilities and expand its comprehensive suite of products and services focused on critical areas including liver safety, liver disease, islet biology, oncology, and immunology.
The investment will enable InSphero to accelerate the development of its state-of-the-art assays and screening platforms, ultimately leading to more effective and safer therapies that can reach clinical trials in record time. By leveraging their superior robustness, reliability, reproducibility, and scalability, InSphero's cutting-edge models are positioned to address the pressing needs in drug discovery, pushing the boundaries of what is possible in therapeutic development. As the company forges ahead, they remain committed to supporting the research community with the tools necessary to combat some of the most challenging health issues of our time. This funding round not only underscores the importance of innovation in the life sciences but also reflects a growing recognition of InSphero's pivotal role in driving a new era of drug development, fostering breakthrough therapies, and ultimately improving patient outcomes.
.png&w=3840&q=75)
